{"id":452,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"cagrilintide-vs-cagrisema-evidence-boundaries","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/cagrilintide-vs-cagrisema-evidence-boundaries\/","title":{"rendered":"Cagrilintide vs CagriSema: mol\u00e9culas, evidencia de ensayos y confusiones comunes"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">Cagrilintide, semaglutida y CagriSema son t\u00e9rminos relacionados, pero no describen la misma intervenci\u00f3n. Las p\u00e1ginas de b\u00fasqueda a menudo fusionan sus evidencias, lo que crea errores f\u00e1cticos y puede implicar una equivalencia que el estudio citado nunca prob\u00f3.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Conclusiones clave<\/h2><ul class=\"wp-block-list\"><li>Cagrilintide activa las v\u00edas de los receptores de amilina; La semaglutida activa el receptor GLP-1.<\/li><li>Los ensayos de CagriSema estudiaron la coadministraci\u00f3n espec\u00edfica de ambos componentes, no todas las combinaciones o proporciones posibles.<\/li><li>Los resultados combinados pertenecen a la intervenci\u00f3n y la poblaci\u00f3n del ensayo; no son promesas gen\u00e9ricas de productos.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\" alt=\"Investigador revisa tres v\u00edas de se\u00f1alizaci\u00f3n de receptores de p\u00e9ptidos en un laboratorio de biolog\u00eda molecular\" class=\"wp-image-442\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-300x169.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1024x576.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-768x432.png 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research-1536x864.png 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">Ilustraci\u00f3n conceptual de distintas v\u00edas de receptores; no representa una mezcla comercial ni un resultado cl\u00ednico.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Tres t\u00e9rminos, tres objetos de evidencia<\/h2><p class=\"wp-block-paragraph\">Cagrilintide es un an\u00e1logo de amilina de acci\u00f3n prolongada. La semaglutida es un agonista del receptor GLP-1 y el ingrediente activo de medicamentos aprobados espec\u00edficos. CagriSema es el nombre utilizado para su coadministraci\u00f3n en determinados programas de desarrollo. El hecho de que dos componentes aparezcan juntos no borra sus identidades separadas ni sus requisitos de calidad.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Cagrilintide<\/strong><span>An\u00e1logo de amilina; evidencia de desarrollo de agente \u00fanico<\/span><\/div><div class=\"pim-evidence-row\"><strong>Semaglutida<\/strong><span>agonista del receptor GLP-1; existen usos aprobados espec\u00edficos del producto<\/span><\/div><div class=\"pim-evidence-row\"><strong>CagriSema<\/strong><span>Coadministraci\u00f3n cl\u00ednica especificada de cagrilintida y semaglutida<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Lo que a\u00f1aden los art\u00edculos 3 de la fase m\u00e1s reciente<\/h2><p class=\"wp-block-paragraph\">Los estudios de fase 3a publicados en 2025 evaluaron cagrilintida-semaglutida en adultos con sobrepeso u obesidad, incluidas poblaciones con diabetes tipo 2. En 2026, REIMAGINE 2 inform\u00f3 una comparaci\u00f3n directa que incluy\u00f3 grupos combinados y de un solo componente para los resultados gluc\u00e9micos en la diabetes tipo 2.<\/p><p class=\"wp-block-paragraph\">Estos registros son valiosos porque sus dise\u00f1os especifican los componentes, el producto de prueba, la poblaci\u00f3n y los puntos finales. No deben abreviarse como \u201ctrabajos de cagrilintida como CagriSema\u201d ni usarse para validar una mezcla de cat\u00e1logo no relacionada.<\/p><h2 class=\"wp-block-heading\">C\u00f3mo una p\u00e1gina combinada debe citar la literatura<\/h2><p class=\"wp-block-paragraph\">Una p\u00e1gina de mezcla responsable debe vincular los registros de identidad de un solo componente, indicar la proporci\u00f3n de cat\u00e1logo real y los controles anal\u00edticos, y citar ensayos de combinaci\u00f3n como contexto de investigaci\u00f3n externo. Tambi\u00e9n deber\u00e1 indicar que la intervenci\u00f3n publicada no establece la calidad, seguridad o eficacia del lote del cat\u00e1logo suministrado.<\/p>","protected":false},"excerpt":{"rendered":"<p>Una comparaci\u00f3n clara de cagrilintida, semaglutida y la combinaci\u00f3n CagriSema estudiada, incluidos los registros de la fase 2025-2026 3 y los l\u00edmites en la transferencia de evidencia.<\/p>","protected":false},"author":1,"featured_media":622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"320,321","pim_article_type":"Comparative evidence explainer","pim_evidence_level":"Phase 2 single-agent and phase 3 combination evidence","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Cagrilintide phase 2 single-agent trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\",\"note\":\"Single-agent evidence.\"},{\"title\":\"CagriSema in adults with overweight or obesity and type 2 diabetes\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40544432\/\",\"note\":\"Phase 3a combination trial; PMID 40544432.\"},{\"title\":\"REIMAGINE 2 cagrilintide-semaglutide comparative phase 3 study\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42251859\/\",\"note\":\"2026 comparative trial; PMID 42251859.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-452","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups - NHD<\/title>\n<meta name=\"description\" content=\"A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025\u20132026 phase 3 records and limits on transferring evidence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/cagrilintide-vs-cagrisema-evidence-boundaries\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups\" \/>\n<meta property=\"og:description\" content=\"A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025\u20132026 phase 3 records and limits on transferring evidence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/cagrilintide-vs-cagrisema-evidence-boundaries\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/\"},\"wordCount\":306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/\",\"name\":\"Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025\u20132026 phase 3 records and limits on transferring evidence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrilintide-vs-cagrisema-evidence-boundaries\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cagrilintide vs CagriSema: mol\u00e9culas, evidencia de ensayos y confusiones comunes - NHD","description":"Una comparaci\u00f3n clara de cagrilintida, semaglutida y la combinaci\u00f3n CagriSema estudiada, incluidos los registros de la fase 2025-2026 3 y los l\u00edmites en la transferencia de evidencia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/cagrilintide-vs-cagrisema-evidence-boundaries\/","og_locale":"es_ES","og_type":"article","og_title":"Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups","og_description":"A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025\u20132026 phase 3 records and limits on transferring evidence.","og_url":"https:\/\/nhdbio.com\/es\/cagrilintide-vs-cagrisema-evidence-boundaries\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/"},"wordCount":306,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/","url":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/","name":"Cagrilintide vs CagriSema: mol\u00e9culas, evidencia de ensayos y confusiones comunes - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Una comparaci\u00f3n clara de cagrilintida, semaglutida y la combinaci\u00f3n CagriSema estudiada, incluidos los registros de la fase 2025-2026 3 y los l\u00edmites en la transferencia de evidencia.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/cagrilintide-vs-cagrisema-evidence-boundaries-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/cagrilintide-vs-cagrisema-evidence-boundaries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=452"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/452\/revisions"}],"predecessor-version":[{"id":519,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/452\/revisions\/519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/622"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}